Merck drops hep C programs in ‘strategic decision’ 

The Scoop About Mavyret
October 17, 2017
Biotin: A Promising Treatment for Progressive MS
October 17, 2017
Show all

Merck drops hep C programs in ‘strategic decision’ 

Merck is no longer as involved in the hepatitis C market.

Dive Brief:

  • Merck & Co. has discontinued the development of two investigational combination regimens that were in testing for the treatment of chronic hepatitis C, citing its review of Phase 2 efficacy data and the current status of the marketplace.
  • The two regimens being dropped are MK-3682B and MK-3682C, both of which contained the experimental uprifosbuvir. Merck said it will maintain its already-marketed hepatitis C offering Zepatier, a fixed dose combination of elbasvir and grazoprevir.
  • This move doesn’t come as entirely unexpected. In February, Merck wrote down the value of hepatitis C drug uprifosbuvir by $2.9 billion, recognizing the drugs’ reduced commercial potential given the competitive nature of the market.

Read full article: Merck drops hep C programs in ‘strategic decision’ | BioPharma Dive

Read Full Article: Merck drops hep C programs in ‘strategic decision’ | BioPharma Dive

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.